



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Itacitinib adipate

Cat. No.: HY-16997A
CAS No.: 1334302-63-4
Molecular Formula: C₃₂H₃₃F₄N₉O₅
Molecular Weight: 699.66
Target: JAK
Pathway: Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Storage: 4°C, stored under nitrogen
 * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 137.5 mg/mL (196.52 mM)

* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.4293 mL	7.1463 mL	14.2927 mL
	5 mM		0.2859 mL	1.4293 mL	2.8585 mL
	10 mM		0.1429 mL	0.7146 mL	1.4293 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (3.57 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (3.57 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.57 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.

IC₅₀ & Target

JAK1

CUSTOMER VALIDATION

-
- Leukemia. 2019 Aug;33(8):1964-1977.
 - EMBO Rep. 2019 Jun;20(6):e47202.
 - EMBO Rep. 2019 Jun;20(6):e47202.
 - J Autoimmun. 2019 May;99:39-47.
 - JCI Insight. 2021 Apr 8;6(7):142205.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Griesshammer M, et al. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. Expert Opin Pharmacother. 2017 Dec;18(18):1929-1938.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA